Atrial fibrillation (AF) is associated with significant impairments in functional capacity and health-related quality of life, as well as with an increased morbidity and mortality. AF is independently associated with a 1.5- to 4-fold increased risk of mortality, predominantly due to increased risk of thromboembolic events (stroke) and ventricular dysfunction.
In this expert brief, Dr. Isabelle Nault and Dr. Bruno Bernucci discuss the benefits of screening for AF, who should be screened, and various screening and imaging methods. They will also touch on the use of oral anticoagulants to reduce the risk of stroke associated with AF.
This program is made possible through educational support from the BMS/Pfizer Alliance.